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Summary
 
Interleukin-4 (IL-4) provides support for humoral immune responses through upregulation of
T helper (Th) type 2 cell differentiation, but it is not known whether IL-4 promotes antibody-
mediated autoimmune diseases such as systemic lupus erythematosus (SLE). Here, we show
that the constitutive expression of an IL-4 transgene by B cells completely prevents the devel-
opment of lethal lupus-like glomerulonephritis in the (NZW 
 
3
 
 C57BL/6.
 
Yaa
 
)F1 murine
model of SLE. This was associated with marked changes in the serum levels of IgG subclasses,
rather than in the total levels of anti-DNA antibodies, with a lack of IgG3, a decrease of IgG2a,
and an increase in IgG1 subclasses, and by a strong reduction in the serum levels of gp70-anti-
gp70 immune complexes. This effect of the transgene appears to result from a modulation of
the Th1 versus Th2 autoimmune response, since the protected mice displayed comparably
modified IgG2a and IgG3 antibody response against exogenous T cell–dependent antigen, but
not against T cell–independent antigens. Thus, IL-4 prevents the development of this lupus-
like autoimmune disease, most likely by downregulating the appearance of Th1-mediated IgG
subclasses of autoantibodies such as the IgG3 autoantibodies which have been shown to be es-
pecially nephritogenic.
 
M
 
ice of the (NZB 
 
3
 
 NZW)F1 hybrid, mice of the
MRL strain homozygous for the 
 
lpr
 
 gene (lympho-
proliferation), and of the BXSB/MpJ strain carrying an au-
toimmune acceleration gene present on the Y chromosome,
 
Yaa
 
 (Y-linked autoimmune acceleration), spontaneously
develop a severe immune complex–mediated glomerulo-
nephritis resembling human SLE (1). The spontaneous pro-
duction of pathogenic IgG autoantibodies in these lupus-
prone mice reflects the intrinsic abnormal hyperactivity of
B cells and their interaction with CD4
 
1
 
 Th cells in which
the pattern of cytokine expression may have important im-
munopathological consequences (2). Among cytokines pro-
duced by Th cells, IL-4 has been shown to have important
regulatory properties on humoral immune responses. First
described as a costimulator for the proliferation of resting
B cells, IL-4 has been also shown to enhance the expression
of Ia molecules on resting B cells, to induce IgG1 and IgE
antibody production, and to play a predominant role in
vitro in the differentiation of CD4
 
1
 
 T cells into the Th
type 2 subset (3). Notably, Th2 cells play an essential role
in some humoral responses through the action of their cy-
tokines such as IL-5, -6, and -10 on B cells (4–6).
In view of the B cell–stimulatory properties and Th2
promoting activity ascribed to IL-4, it can be speculated
that IL-4 may be involved in the development of autoanti-
body-mediated autoimmune diseases such as SLE. In fact,
IL-4 has been shown to be an important mediator in the
pathogenesis of murine lupus-like diseases induced by graft-
versus-host and host-versus-graft reactions, or by chemicals
(7). This notion is also supported by the findings that treat-
ment of lupus-prone (NZB 
 
3
 
 NZW)F1 mice with mAbs
specific for the Th2-related cytokines IL-6 or -10 markedly
delays onset of autoimmune disease (8, 9), and that admin-
istration of IL-5 or -10 is able to induce autoimmune ane-
mia in anti-RBC autoantibody transgenic mice (10). It is,
however, not yet known whether IL-4 promotes disease
development in spontaneous murine models of SLE.
To address this question, we determined the effect of
constitutive expression of an IL-4 transgene by B cells on
the development and progression of lupus-like syndrome.
For this purpose, we have used the (NZW 
 
3
 
 C57BL/
6.
 
Yaa
 
)F1 murine model of SLE (11), in which the develop-
ment of an autoimmune syndrome in male mice is depen-
dent on the abnormal autosomal NZW genome, and the
presence of an unidentified mutant gene 
 
Yaa
 
 located on the
Y chromosome derived from the lupus-prone BXSB strain
(12). The IL-4 transgene was introduced into this lupus-
prone background by crossing C57BL/6.
 
Yaa
 
 (B6.
 
Yaa
 
) males
with females of the 129/Sv–IL-4 transgenic strain, which
contains a single copy of murine IL-4–encoding cDNA
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under the control of IgH enhancer/promoter (13), and
then crossing the F1 male progeny with NZW females.
Our analysis of the development of SLE in these lupus-
prone mice indicates that the constitutive expression of the
IL-4 transgene in B cells does not promote, but prevents,
the development of lupus-like autoimmune syndrome, and
provides a possible explanation for the capacity of IL-4 to
control SLE by downregulating Th1-mediated IgG sub-
classes of autoantibodies.
 
Materials and Methods
 
Mice.
 
The 129/Sv IL-4 transgenic mutant strain (pEP-IL-4),
which contains one copy of murine IL-4–encoding cDNA under
the control of IgH enhancer/promoter, was generated by trans-
fecting a murine-embryonic stem cell line with an IL-4 expres-
sion vector, described previously (13). B6.
 
Yaa
 
 mice were estab-
lished by backcross procedures, as described previously (11).
NZW mice were purchased from Harlan Olac Ltd. (Oxon, UK).
NZW 
 
3
 
 (pEP-IL-4 
 
3
 
 B6.
 
Yaa
 
) mice were obtained by local
breeding in our own animal facility. The inheritance of IL-4
transgene was ascertained by assessing an increased Ia expression
by peripheral blood B lymphocytes. Blood samples were col-
lected by orbital sinus puncture, and the sera were stored at
 
2
 
20
 
8
 
C until use.
 
mAb and Cytofluorometric Analysis.
 
The following mAbs were
used: LO-MM-9 (anti–mouse 
 
m
 
 chain), Y-3P (anti-I-A
 
b
 
), and
H81.98.21.1 (anti-I-E). For immunofluorescence analysis, mAbs
were purified on protein G–sepharose and coupled to FITC or
biotin; staining the cells was done as described by Rolink et al.
(14). PE-labeled avidin was purchased from CALTAG Labs.
(South San Francisco, CA). Spleen cells from 2-mo-old mice
were first stained with FITC-labeled anti–mouse 
 
m
 
 chain mAb,
and then incubated in absence or in presence of biotinylated anti-
I-A or I-E mAb’s, before incubation with PE-labeled avidin. 10
 
4
 
events were analyzed with a lymphocyte gate as defined by light
scatter with a FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA).
 
Antigens and Immunization Protocols.
 
Mice were immunized in-
travenously with 400 
 
m
 
g of heat-aggregated human IgG (HGG)
 
1
 
in PBS or 10 
 
m
 
g (4-hydroxy-3-iodo-5-nitrophenyl) acetyl (NIP)-
Ficoll in PBS. NIP-Ficoll was a gift from Dr. A. Rolink (Basel
Institute for Immunology, Basel, Switzerland). Sera were col-
lected 10 d later. LPS-induced polyclonal Ig responses were de-
termined by injecting mice intraperitoneally with 25 
 
m
 
g LPS
from 
 
Salmonella minnesota
 
 R595, and collecting sera 8 d later for
IgM analysis, and 15 d later for IgG subclass analysis.
 
Serological Assays.
 
Total levels of serum IgM and IgG sub-
classes were determined by ELISA as previously described (15),
using alkaline phosphatase-labeled goat antibodies specific for
mouse Ig classes and subclasses (purchased from Southern Bio-
technology Assoc., Birmingham, AL). The Ig concentrations were
determined by referring to standard curves obtained with known
concentrations of mouse Ig (Southern Biotechnology Assoc., and
ICN Biomedicals, Inc., Costa Mesa, CA).
The presence of IgG anti–DNA antibodies was assessed by
ELISA as previously described (15). Results are expressed in titra-
tion units (U/ml) in reference to a standard curve obtained from
3–4-mo-old MRL-
 
lpr
 
/
 
lpr
 
 mice. Titers of IgG subclass anti–DNA
were determined by ELISA using IgG subclass specific antibodies
(Southern Biotechnology Assoc.). The titers are the highest dilu-
tions still giving a positive signal (log2 titers) in the ELISA, in
which twofold serum dilutions were tested starting from 1:100
dilution.
Serum levels of gp70-anti–gp70 immune complexes (gp70 IC)
were quantified by ELISA combined with the precipitation of the
serum with polyethylene glycol (average molecular weight 6,000),
which precipitates only the antibody-bound gp70, and not free
gp70, as described (16). Results are expressed as 
 
m
 
g/ml of gp70
complexed with anti-gp70 autoantibodies by referring to a standard
curve obtained from NZB sera with known amounts of gp70.
Serum levels of IgM and IgG subclasses of anti-HGG and anti–
NIP antibodies were measured by ELISA in which HGG or
NIP
 
15
 
-BSA were used as coating antigens. Titers of anti-HGG
and anti-NIP of individual Ig isotypes are expressed as the highest
serum dilution giving a positive signal (log2 titers) in the ELISA,
in which twofold serum dilutions were tested starting from 1:100
dilution.
 
Histopathology.
 
Samples of all major organs were obtained at
autopsy, and histological sections were stained with periodic
acid–Schiff reagent. Glomerulonephritis was evaluated based on
the intensity and extent of pathological changes as described (11).
 
Statistical Analysis.
 
Statistical analysis was performed with the
Wilcoxon two-samples test. 
 
P
 
 
 
.
 
5% were considered insignifi-
cant.
 
Results
 
Prevention of Lupus-like Nephritis By IL-4 Transgene Ex-
pression in the (NZW 
 
3
 
 B6.Yaa)F1 Murine Model of SLE.
 
To determine whether constitutive IL-4 transgene expres-
sion may influence the development of the autoimmune
SLE syndrome in (NZW 
 
3
 
 B6.
 
Yaa
 
)F1 mice, pEP-IL-4 fe-
male transgenic mice were crossed with B6.
 
Yaa
 
 males, and
the resulting (pEP-IL-4 
 
3
 
 B6.
 
Yaa
 
)F1 male mice bearing
the IL-4 transgene and the 
 
Yaa
 
 gene were then crossed
with NZW females, thus generating lupus-prone NZW 
 
3
 
(pEP-IL-4 
 
3
 
 B6.
 
Yaa
 
) male mice. Consistent with previous
analysis of pEP-IL-4 transgenic mice (13), most splenic B
cells of IL-4 transgenic NZW 
 
3
 
 (pEP-IL-4 
 
3
 
 B6.
 
Yaa
 
)
mice exhibited a markedly increased (5–10-fold) expression
of I-A and I-E molecules, as compared with nontransgenic
littermates (Fig. 1 
 
A
 
).
The male nontransgenic littermates spontaneously devel-
oped a lethal form of lupus-like glomerulonephritis, as ob-
served in (NZW 
 
3
 
 B6.
 
Yaa
 
)F1 male mice (11). 46% (16/35)
of the nontransgenic males died of glomerulonephritis by
9 mo after birth and 86% (30/35) at 12 mo. In contrast, the
development of lupus-like glomerulonephritis was dramati-
cally prevented in the male transgenic mice; only 1/38
transgenic mice died of glomerulonephritis within the first
year (Fig. 1 
 
B
 
) and beyond (18 mo). At 8 mo, transgenic
males showed only minimal glomerular alterations, which
markedly contrasted with the severe glomerular lesions
observed in the surviving nontransgenic male littermates
(Fig. 1 
 
C
 
).
 
Serological Characteristics in the IL-4 Transgenic Mice. 
 
The
protective effect of the IL-4 transgene did not appear to be
 
1
 
Abbreviations used in this paper:
 
 gp70 IC, gp70-anti-gp70 immune com-
plex; HGG, human IgG; NIP, 4-hydroxy-3-iodo-5-nitrophenyl acetyl. 
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associated with a reduction of total serum IgG anti-DNA
autoantibodies (although titers were 1.5-fold lower in IL-4
transgenic mice; 4 mo: 
 
P
 
 
 
,
 
0.05, 8 mo: 
 
P
 
 
 
.
 
0.1, Fig. 2 
 
A
 
),
but rather with marked changes in IgG subclasses (Fig. 2
 
B
 
). In fact, IgG3 anti-DNA antibodies were barely detect-
able in transgenic mice (
 
P
 
 
 
,
 
0.0001) even at one year of age
(data not shown), and IgG2a anti-DNA antibodies were re-
duced (
 
P
 
 
 
,
 
0.001), while IgG1 anti-DNA levels were in-
creased in the transgenic mice (
 
P
 
 
 
,
 
0.05). Total IgG subclass
levels also differed in transgenic mice in a comparable way;
there was a two– to fourfold increase of IgG1 (
 
P
 
 
 
,
 
0.005),
but two-fold and 10-fold decreases of IgG2a (
 
P
 
 
 
,
 
0.001)
and IgG3 (
 
P
 
 
 
,
 
0.0001), respectively (Fig. 2 
 
C
 
).
To further characterize the basis for the IL-4 protection,
transgenic mice were analyzed for the serum levels of gp70
IC, which have been demonstrated to best correlate with
the development of murine lupus nephritis (17–19). Re-
sults of this analysis, presented in Fig. 2 
 
D
 
, indicate that
amelioration of clinical manifestations was accompanied by
a strong reduction of circulating gp70 IC levels at 4 and
8 mo in nontransgenic males (4 mo: 9.2 
 
6
 
 7.3 
 
m
 
g/ml, 8 mo:
9.2 
 
6
 
 8.6 
 
m
 
g/ml), as compared to transgenic males (4 mo:
0.4 
 
6
 
 0.5 
 
m
 
g/ml, 
 
P
 
 
 
,
 
0.0001, 8 mo: 2.2 
 
6
 
 2.3 
 
m
 
g/ml,
 
P ,0.001).
Reduced Production of IgG2a and IgG3 versus IgG1 Antibod-
ies Against T Cell–dependent, But Not T Cell–independent, An-
tigens in IL-4 Transgenic Mice.  The changes in IgG sub-
classes may result from a direct effect of the transgenic IL-4
expressed by the B cells on these cells, or from an IL-4 ac-
tion modulating the Th1 and Th2 responses; IFN-g pro-
duced by Th1 cells and IL-4 secreted by Th2 cells are
known to regulate reciprocally IgG class switching, the
former promoting the Ig switch to IgG2a and IgG3 sub-
classes, and the latter to the IgG1 subclass (20, 21). To ad-
Figure 1. Prevention by the IL-4 transgene of the spontaneous devel-
opment of lupus-like glomerulonephritis in lupus-prone NZW 3 (pEP-
IL-4 3 B6.Yaa) mice. (A) Increased expression of MHC class II mole-
cules on surface IgM1 B cells in 2-mo-old NZW 3 (pEP-IL-4 3
B6.Yaa) male mice bearing the IL-4 transgene, as compared with non-
transgenic littermates. Spleen cells were stained with FITC-labeled anti–
mouse m chain mAb, and then incubated in absence (normal line) or in
presence (bold line) of biotinylated anti-I-A (upper panel) or anti-I-E (lower
panel) mAb’s, followed by PE-conjugated avidin. (B) Cumulative mortal-
ity with glomerulonephritis in IL-4 transgenic (n 5 38) (closed circle) and
non transgenic (n 5 35) (open circle) male mice. (C) Representative histo-
logical appearance of glomeruli from 8-mo-old IL-4 transgenic and non-
transgenic male mice. Note increased glomerular cellularity and oblitera-
tion of the glomerular architecture in nontransgenic males, which contrast
with the minimal alterations in glomeruli from transgenic mice. The tis-
sues were stained with periodic acid-Schiff reagent (3200).
Figure 2. Effect of the IL-4 transgene expression on the spontaneous
autoantibody and IgG production in lupus-prone NZW 3 (pEP-IL-4 3
B6.Yaa) mice. (A) Levels of serum IgG anti–DNA antibodies in IL-4
transgenic (Tg) and nontransgenic (N-Tg) male mice 4 and 8 mo-old. Re-
sults are expressed in U/ml by reference to a standard curve obtained with
a serum pool of 3–4-mo-old MRL-lpr/lpr mice. (B) IgG1, IgG2a, and
IgG3 subclass distribution of anti–DNA antibodies in the sera of 6-mo-old
IL-4 transgenic and nontransgenic male mice. Twofold serum dilutions
were tested starting with 1:100 dilution. The titers are the highest dilu-
tions still giving a positive signal in the ELISA. (C) Serum levels of IgG1,
IgG2a, and IgG3 subclasses in 4-mo-old IL-4 transgenic and nontrans-
genic male mice. Ig concentrations are expressed in mg/ml. The means of
16 mice (6 1 SD) are represented. (D) Serum levels of gp70 IC in IL-4
transgenic and nontransgenic male mice 4 and 8 mo old. Results are ex-
pressed in mg/ml. Each symbol represents the value from individual ani-
mals. The median values are indicated as horizontal lines.68 IL-4 Protection against Murine Lupus Nephritis
dress this question, transgenic mice and their nontransgenic
littermates were immunized either with the T cell–depen-
dent antigen, HGG, the T cell-independent antigen NIP-
Ficoll, or stimulated by the injection of LPS, a polyclonal
B cell activator. Transgenic mice developed a limited IgG2a
and IgG3 response (P ,0.005), but a comparable IgG1
anti–HGG response (Fig. 3 A), whereas no significant dif-
ferences in IgG subclass responses were observed in the anti–
NIP antibody response in both groups of mice (Fig. 3 B).
In addition, the pattern of antigen-nonspecific polyclonal
Ig production following the injection of LPS was essen-
tially identical in both groups of mice, except for a greater
increase of IgG3 in transgenic mice, which is likely to be
related to the fact that basal levels of IgG3 were markedly
diminished in the latter mice (Fig. 3 C).
Discussion
The role of IL-4 in systemic autoimmunity was investi-
gated here by studying the effects of an IL-4 transgene on
the development of autoimmune disease in the (NZW 3
B6.Yaa)F1 murine model of SLE. Our data demonstrate that
the constitutive expression of an IL-4 transgene by B cells
did not promote, but protected mice against the spontane-
ous development of lupus-like glomerulonephritis. We also
showed that this protection occurred in association with
marked changes in the IgG subclasses rather than in the
total levels of anti–DNA autoantibodies, with an absence
of IgG3 and a decrease of IgG2a subclasses. This was ac-
companied by a similar modulation of the IgG subclass of
T cell–dependent antibody responses, but not T cell–inde-
pendent antibody responses, suggesting a causal link be-
tween IL-4, downregulation of Th1 autoimmune responses,
and protection against SLE disease.
The protection from SLE in association with the changes
in IgG subclass responses as a result of the IL-4 transgene
expression by B cells can be mediated either by a direct ef-
fect of the transgenic IL-4 on B cells, or by an IL-4 action
on the modulation of the Th1 and Th2 responses. How-
ever, the lack of effect of the IL-4 transgene on the induc-
tion of IgG1 antibody production during T cell–indepen-
dent (antigen-specific and nonspecific) activation of B cells
strongly argues against a direct effect of the IL-4 transgene
on the IgG class switching in B cells. This may be due in
part to a low level of expression of the IL-4 transgene (13),
as the pEP-IL-4 transgenic mice do not spontaneously ex-
hibit any significant isotype alterations, although the trans-
gene expression is sufficient to maintain Ia hyperexpression
on B cells. Instead, the results obtained with the stimulation
with T cell–dependent antigen suggest that the decrease of
IgG3 and IgG2a autoantibody production in the transgenic
mice is most likely due to the inhibitory effect of IL-4 on
the development of the Th1 subset. This is consistent with
the previous demonstration that pEP-IL-4 transgenic mice
are more susceptible to Leishmania major infection than
nontransgenic mice (22) in which Th1 cells play a crucial
role in protection against L. major infection (23). The lack
of effect on IgM and IgG3 antibody responses to T cell–
independent antigens, together with the absence of signifi-
cant effect on the serum levels of IgM antibodies reactive
with bromelain-treated mouse red blood cells and the total
number of IgMbright IgDdull, Mac-11 B-1 peritoneal cells
(our unpublished results), further rule out an IL-4 effect
not mediated by T cells.
The beneficial effect of the IL-4 transgene is thus likely
to be a result of a downregulation of Th1 responses in-
volved in autoantibody production in our murine SLE
model. This notion is supported by our recent observation
that the progression of lupus nephritis in MRL mice bear-
ing the Yaa or lpr (Fas) mutation correlates with an in-
creased production of IgG2a and IgG3 versus IgG1 anti-
bodies in parallel to an enhanced expression of IFN-g
versus IL-4 mRNA by CD41 T cells (24). In addition, it
has been shown that repeated injections of recombinant
IFN-g can accelerate the development of SLE, and treat-
ment with anti–IFN-g mAb or soluble IFN-g receptors
can inhibit the progression of SLE in (NZB 3 NZW)F1
mice (25, 26). Although one cannot rule out the possibility
that proinflammatory Th1 cytokines may be involved in
the immunopathogenetic process of glomerular lesions thus
Figure 3. Effect of the IL-4 transgene on antigen-specific and nonspe-
cific antibody production during T cell–dependent and T cell–indepen-
dent antibody responses in NZW 3 (pEP-IL-4 3 B6.Yaa) mice. IgM and
IgG subclass distribution of anti–HGG (A) and anti–NIP (B) specific anti-
bodies in 3–5-mo-old IL-4 transgenic (closed circle) and nontransgenic
(open circle) male mice 10 d after immunization with T cell–dependent an-
tigen HGG, or T cell–independent antigen NIP-Ficoll. IgG anti–HGG
antibodies were undetectable in sera from both transgenic and nontrans-
genic mice before immunization. While IgG anti–NIP antibodies were
undetectable, sera from both groups of mice before immunization exhib-
ited significant and comparable titers of IgM anti–NIP antibodies (detect-
able at a serum dilution of 1:800), and their levels increased zeightfold af-
ter immunization. Each symbol represents the value from one individual.
(C) LPS-induced polyclonal IgM and IgG subclass responses in 6-mo-old
IL-4 transgenic (right) and nontransgenic mice (left). IgM and IgG subclass
levels determined 8 and 15 d, respectively, after the LPS injection (filled
column), were compared with those before the injection (open column).
The number in parentheses indicates the fold-increase of each Ig isotype
after the LPS injection. The means of five mice (6 1 SD) are shown.69 Santiago et al.
participating in the progression of the disease, an attractive
possibility is that IFN-g producing Th1 cells may promote
the production of autoantibodies with more immuno-
pathological consequences. It has been shown that murine
IgG3 mAb are extremely nephritogenic, and generate lu-
pus-like glomerular lesions through their cryoglobulin ac-
tivity related to the unique structure of the g3 constant re-
gion (27, 28). Several studies have also shown that IgG3
levels correlate well with the development of murine lupus
nephritis (24, 29–31). In addition, the complement activat-
ing IgG2a antibodies may be more nephritogenic than
IgG1 antibodies. Although the IgG subclasses present in the
gp70 IC have not been established, treatments such as early
thymic irradiation, which retard the progression of SLE in
(NZB 3 NZW)F1 mice, lead to a selective decrease in the
levels of both IgG3 and gp70 IC (31), suggesting that IgG3
may be one of the major IgG subclasses of anti-gp70 au-
toantibodies; this would explain the remarkable suppression
of the gp70 IC in the IL-4 transgenic mice.
When interpreting the protection given by IL-4 trans-
gene expression against this murine SLE, it should not be
assumed that the autoimmune manifestations of the SLE
disease are based solely on a Th1 type autoimmune re-
sponse, since Th2 type cytokines such as IL-6 and -10 are
apparently involved (8, 9), perhaps in relation to these cy-
tokines’ ability to augment the overall production of patho-
genic autoantibodies by promoting the terminal differentia-
tion of activated B cells (4–6). In fact, many immune
responses do not reflect an absolute Th1 or Th2 pattern,
but seem to be functionally dominated either by Th1
(IFN-g) or Th2 (IL-4) cytokines (3), and therefore, as sug-
gested by a study of Klinman and Steinberg (32), an altered
ratio of IFN-g/IL-4 producing T cells could determine the
nature, strength, and duration of systemic autoimmune re-
sponses. It should also be noted that the spontaneous pro-
duction of IgG anti-DNA autoantibodies in lupus-prone
(NZB 3 NZW)F1 mice was shown to reflect the intrinsic
abnormality of B cells, as well as their hyperactivity to nor-
mal levels of immunostimulatory cytokines such as IL-5
(33, 34). Clearly, it will be important to determine whether
IL-4 transgene expression also leads to protection against
SLE in other murine models such as (NZB 3 NZW)F1
and MRL-lpr/lpr mice, and to address the issue of whether
IL-4–induced immune deviation can provide protection from
ongoing disease (35), since this would help establish new
strategies for the development of therapeutic approaches in
SLE and related human autoimmune diseases.
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